Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC By Ogkologos - August 11, 2026 53 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COMMIT study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR No Survival Benefit from Adding Preoperative Chemoradiotherapy to Perioperative Chemotherapy in... September 26, 2024 How will new cancer medicines be approved in the future? December 2, 2021 EMA Recommends Extension of Indications for Venetoclax May 14, 2021 Mouse Study Points to Strategy for Preserving Bone During Chemotherapy February 25, 2020 Load more HOT NEWS ESMO Highlights the Importance of Prioritising the Fight Against Cancer in... Sacituzumab Govitecan Plus Pembrolizumab Demonstrate Encouraging Activity in Patients with mUC... ESMO Highlights the Importance of a Strong EU Commitment Towards Robust... Neoadjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy Can Be Delivered Safely in Patients with Operable...
